Bay City Capital Overview

  • Investor Type
  • Venture Capital

  • Status
  • Active

  • Professionals
  • 5

Professionals

  • Investments
  • 174

  • Portfolio
  • 7

  • Exits
  • 115

Exits

Bay City Capital General Information

Description

Founded in 1997, Bay City Capital is a venture capital firm based in San Rafael, California. The firm seeks to invest in the life sciences industry, with a focus on investing in companies within the bio-pharmaceuticals, drug discovery, medical devices, nutrition, healthcare IT, and medical diagnostics sectors.

Contact Information

Website
www.baycitycapital.com
Year Founded
1997
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Mezzanine
PE/Buyout
Primary Office
  • 1000 4th Street
  • Suite 500
  • San Rafael, CA 94901
  • United States
+1 (415) 000-0000

Bay City Capital Investments (174)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Oculis 28-Apr-2021 Later Stage VC 000.00 Drug Discovery Generating Revenue/Not Profitable 000000 000000
Bridge Medicines 12-Nov-2020 00000 00000 0000 Drug Discovery Generating Revenue
Xilio Therapeutics 02-Mar-2020 00000 00000 00000 Drug Discovery Clinical Trials - Phase 1
Imara 01-Feb-2020 00000 00000 000.00 Biotechnology Profitable 0000 00000000000 00
NextCure 13-Nov-2018 00000 00000 0000 Biotechnology Pre-Clinical Trials
Gossamer Bio 20-Jul-2018 00000 00000 00000 Drug Discovery Generating Revenue
Twist Bioscience 02-Apr-2018 00000 00000 00000 Drug Discovery Generating Revenue/Not Profitable 000000000 000000 00.0
Iterum Therapeutics 16-Feb-2018 00000 00000 000.00 Drug Discovery Generating Revenue 000000 0000000 00.0
Xeris Pharmaceuticals 13-Feb-2018 Later Stage VC 0000 Drug Discovery Generating Revenue/Not Profitable
Kbp Biosciences 05-Jan-2018 Later Stage VC 0000 Drug Discovery Generating Revenue 000000000 000000 00.0
You’re viewing 10 of 174 investments. Get the full list »

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bay City Capital Exits (115)

Company Name Exit Date Exit Type Exit Size
Oculis 28-Feb-2023 Reverse Merger 00000
Madrigal Pharmaceuticals 23-Dec-2022 000000 0000000000 0000
Cydan 31-Dec-2021 000 00 00000000
Xilio Therapeutics 22-Oct-2021 000 00000
Galecto 29-Oct-2020 000 0000
Imara 12-Mar-2020 000 000.00
Dermira 20-Feb-2020 000000000000000000 00000
PharmAkea Therapeutics 31-Dec-2019 000000000000000000 000.00
ATXCo 25-Sep-2019 Merger/Acquisition
NextCure 09-May-2019 IPO 0000
You’re viewing 10 of 115 exits. Get the full list »

Bay City Capital Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Bay City Capital‘s full profile, request access.

Request a free trial

Bay City Capital Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Bay City Capital Team (40)

Name Title Deals Funds Boards Office
Susan Vuong Chief Financial Officer & Chief Compliance Officer San Rafael, CA
Frederick Craves Ph.D Founder & Managing Director 00 0 0 San Rafael, CA
David Beier JD Managing Director 0 San Rafael, CA
Larry Clay Controller San Rafael, CA
Matthew Kronmiller Vice President San Rafael, CA
You’re viewing 5 of 40 team members. Get the full list »